Abstract
There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, nonspecific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia. This study reports the potent in vitro activity of solithromycin against a collection of recent isolates of Bordetella pertussis.
Highlights
There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine
Azithromycin remains one of the recommended drugs for the treatment and prophylaxis of pertussis, but an alternate drug is needed. This is because resistance to azithromycin among other respiratory pathogens, such as Streptococcus pneumoniae [4, 5], Streptococcus pyogenes [6] and Mycoplasma pneumoniae [7], has been reported, and azithromycin cannot be used in monotherapy when these antibiotic-resistant pathogens are suspected
The MICs of solithromycin, azithromycin, clarithromycin, doxycycline, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanate were generally lower in media with sheep blood than the MICs determined in media with horse blood; these differences, do not suggest interpretive differences in the MICs between the two media
Summary
There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can have a persistent, nonspecific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Azithromycin remains one of the recommended drugs for the treatment and prophylaxis of pertussis, but an alternate drug is needed This is because resistance to azithromycin among other respiratory pathogens, such as Streptococcus pneumoniae [4, 5], Streptococcus pyogenes [6] and Mycoplasma pneumoniae [7], has been reported, and azithromycin cannot be used in monotherapy when these antibiotic-resistant pathogens are suspected. (Part of this research was presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 10 to 13 September 2013 [11].)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
